What: Clinical data analysis experts from Novartis, Astra-Zeneca and Roche will present real-world examples of how they’re driving shorter development cycles and fast, safe product approvals by using analytics to easily access, monitor and understand clinical data. This 90-minute complimentary Webcast, hosted by TIBCO Spotfire, will discuss how these companies are leveraging the TIBCO Spotfire® Enterprise Analytics platform to ease information access to disparate data sources and enable informative instream monitoring of complex clinical data.
On this webcast, you will learn how to:
- Inform early-stage trial design and dose selection with interactive analysis of multivariate clinical data
- Understand and assess drug safety data during clinical pharmacology studies through instream medical monitoring
- Provide safety assessment in pre-clinical and clinical studies through exploratory analysis
When: Wednesday, April 22, 2009 at 10:00 a.m. ET.
Session Details:
Webcast Information: To register for this Webcast, go to: http://goto.spotfire.com/g/?EJPERK7S9U=clicksrc:pr
About TIBCO
TIBCO Software Inc. (NASDAQ: TIBX) is a leading provider of enterprise analytics software for next generation business intelligence. TIBCO Spotfire products offer a visual and interactive experience that helps professionals quickly discover new and actionable insights in information. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value. Spotfire customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit http://spotfire.tibco.com.
###
TIBCO, TIBCO Software and TIBCO Spotfire are trademarks or registered trademarks of TIBCO Software Inc. or its subsidiaries in the United States and/or other countries. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.